Regeneron gains on US FDA acceptance of VEGF Trap-Eye in wet AMD
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review Regeneron Pharmaceuticals' biologics license application (BLA) for its VEGF Trap-Eye (aflibercept) as a treatment for wet age-related macular degeneration (AMD).